BDBM350332 (S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naphthyridin-6-yl)-1H-1,2,4-triazol-5(4H)-one::US10307414, Example 16::US9801872, Example 16
SMILES: C=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2cccnc12)-c1n[nH]c(=O)[nH]1
InChI Key: InChIKey=KKKLCLKIYSMDNV-NSHDSACASA-N
Data: 2 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM350332 ((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <3.16 | n/a | n/a | n/a | n/a | n/a | n/a |
CNRS | Assay Description The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m... | Bioorg Med Chem Lett 19: 1600-3 (2009) BindingDB Entry DOI: 10.7270/Q2TQ63WG | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase BTK (Homo sapiens (Human)) | BDBM350332 ((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <3.16 | n/a | n/a | n/a | n/a | n/a | n/a |
Takeda Pharmaceutical Company Limited US Patent | Assay Description The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m... | US Patent US9801872 (2017) BindingDB Entry DOI: 10.7270/Q2BC41PD | |||||||||||
More data for this Ligand-Target Pair |